Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales Clinical School, UNSW Sydney, Sydney, NSW 2052, Australia; School of Materials Science and Engineering, UNSW Sydney, Sydney, NSW 2052, Australia.
Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales Clinical School, UNSW Sydney, Sydney, NSW 2052, Australia.
Drug Discov Today. 2022 Dec;27(12):103386. doi: 10.1016/j.drudis.2022.103386. Epub 2022 Sep 29.
Inorganic nanoparticles for drug delivery in cancer treatment offer many potential advantages because they can maximize therapeutic effect through targeting ligands while minimizing off-target side-effects through drug adsorption and infiltration. Although inorganic nanoparticles were introduced as drug carriers, they have emerged as having the capacity for combined therapeutic capabilities, including anticancer effects through cytotoxicity, suppression of oncogenes and cancer cell signaling pathway inhibition. The most promising advanced strategies for cancer therapy are as synergistic platforms for RNA interference (siRNA, miRNA, shRNA) and as synergistic drug delivery agents for the inhibition of cancer cell signaling pathways. The present work summarizes relevant current work, the promise of which is suggested by a projected compound annual growth rate of ∼ 20% for drug delivery alone.
用于癌症治疗的药物递送的无机纳米粒子提供了许多潜在的优势,因为它们可以通过靶向配体使治疗效果最大化,同时通过药物吸附和渗透使非靶向副作用最小化。尽管无机纳米粒子最初被引入作为药物载体,但它们已经显示出具有联合治疗能力的潜力,包括通过细胞毒性、抑制癌基因和抑制癌细胞信号通路来发挥抗癌作用。癌症治疗最有前途的先进策略是作为 RNA 干扰 (siRNA、miRNA、shRNA) 的协同平台,以及作为协同药物递送剂来抑制癌细胞信号通路。本工作总结了相关的当前工作,预计仅药物递送的复合年增长率就约为 20%,这表明其具有广阔的前景。